Verteporfin PDT for non-standard indications—a review of current literature
Authors:
- 17 February 2010
- journal article
- review article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 248 (5) , 613-626
Abstract
Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the underlying pathology of ocular vascular disorders through its angio-occlusive mechanism of action, which reduces both visual acuity loss and the underlying leakage associated with lesions. Verteporfin PDT has also been associated with encouraging treatment outcomes in case studies involving patients with choroidal vascular disorders such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, choroidal haemangioma, angioid streaks, and inflammatory CNV, i.e. conditions currently considered as non-standard indications of verteporfin PDT. In many studies, outcomes were better than expected based on the natural courses of each of these conditions. Although the anti-vascular endothelial growth factor (VEGF) therapies, ranibizumab and pegaptanib, have been approved for CNV due to AMD, their role in these other choroidal vascular disorders remains to be established. We summarize current literature that has documented the use of verteporfin PDT in these conditions.Keywords
This publication has 100 references indexed in Scilit:
- Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, JapanOphthalmologica, 2009
- Application of Intravitreal Bevacizumab for Circumscribed Choroidal HemangiomaKorean Journal of Ophthalmology, 2009
- Severe choroidal ischemia following Photodynamic Therapy for pigment epithelial detachment and chronic central serous chorioretinopathyJapanese Journal of Ophthalmology, 2009
- Photodynamic therapy for polypoidal choroidal vasculopathy: Vaso-occlusive effect on the branching vascular network and origin of recurrenceJapanese Journal of Ophthalmology, 2008
- The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal VasculopathyKorean Journal of Ophthalmology, 2008
- Photodynamic Therapy for Age-Related Macular Degeneration in Japanese Patients: Results After One YearJapanese Journal of Ophthalmology, 2007
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyBritish Journal of Ophthalmology, 2006
- Photodynamic therapy of circumscribed choroidal haemangiomaBritish Journal of Ophthalmology, 2004
- Photodynamic therapy of circumscribed choroidal hemangiomaOphthalmology, 2003
- Photodynamic therapy for symptomatic choroidal hemangiomaOphthalmology, 2002